Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

University Hospital Groningen, Groningen, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:5City/State/Province:Groningen
Treatments:ChemotherapyHospital:University Hospital Groningen
Drugs:Journal:Link
Date:Jan 2005

Description:

Patients: This Phase II study involved 108 patients. The patients were divided into two groups. 52 patients were assigned to Group B. The median age of Group B was 58, and twenty were women. 41 patients had Stage IV NSCLC, and 11 had Stage IIIb. All patients had been given previous chemotherapy, and 18 had been given previous radiotherapy.

Treatment: The treatment for patients in Group B consisted of two chemotherapeutic drugs -- docetaxel, and irinotecan -- with a white-blood-cell-stimulating drug -- lenogastrim.

Toxicity: Two patients died from the toxicity of treatment. Grade 1-4 hematologic toxicities included: thrombocytopenia, granulocytopenia, leucopenia, and anemia. Grade 1-3 non-hematologic toxicities included: diarrhea, motoric neuropathy, and enzyme concentrations (aspartate aminotransferase and creatinine).

Results: The median survival for Group B was 6.2 months (27 weeks).

Support: Aventis was involved with this study. Aventis manufactures and/or markets docetaxel and irinotecan.

Correspondence: H. J. M. Groen, MD





Back